28 May 2024
Annual General Meeting of Ipsen S.A. held on 28 May 2024
27 May 2022
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different…
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…
13 February 2023
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line…
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 141 Press Releases
20 June 2025
20 June 2025
LinkedIn
Facebook
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 20 June 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients…
31 May 2025
31 May 2025
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS)…
07 May 2025
07 May 2025
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
PARIS, FRANCE, 7 May 2025 Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO® (elafibranor) during the European Association for the Study of the Liver congress.
06 May 2025
06 May 2025
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership…
24 April 2025
24 April 2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver (EASL) congress as…
Your dedicated contacts
-
Media Relations
